Emergent
400 Professional Drive, Suite 400
Gaithersburg, MD 20879
T: +1 (800) 441-4225
E: cdmo@ebsi.com
W: https://emergentCDMO.com
LinkedIn: https://www.linkedin.com/showcase/emergent-biosolutions-cdmo
Synchronized to Serious Science. Yours.
As an integrated CDMO with the experience of an established biopharmaceutical company, Emergent has the scientific and regulatory compliance experience, end-to-end development and manufacturing resources, and efficient technology transfer capabilities that can harness the urgency, acuity, and scalability required to bring life-saving, life-extending products to market. Whether you’re looking for initial process development support, small volumes of material for clinical trials, or large-scale production for a global commercial therapy, our experienced team is ready to serve as your trusted guide from molecule to market.
Development & Manufacturing Solutions for Biologics
Our mission is to protect and enhance life through innovation. Over the last few decades, we have developed, manufactured, and delivered therapeutics and vaccines throughout the world to tackle the most serious public health threats. As a dedicated and experienced global biologics solutions provider, we have supported the development and manufacture of over 40 commercial and more than 100 clinical programs for our biopharma clients.
Technologies & Platforms for Every Strategy
Our development and manufacturing teams have flexible and scalable technology platforms able to support clinical through commercial production.
Development Services
Drug Substance Manufacturing
Drug Product Manufacturing
Wherever you are in your journey, whatever challenges you face, our team of experts and resources are ready to go to work for you.
Let’s get started with your next clinical or commercial candidate. Your biggest challenges inspire us.
Recent Webinars
Large Molecule Outsourced Pharma Capacity Update
Bridging the Gap Between R&D and Manufacturing
Whitepapers
How CDMOs Can Support Nanoparticles for Gene Therapy, Immuno-Oncology and Vaccines
Streamlining Your Process Development Journey to GMP Manufacturing
Benefits of RABS and Isolator Technology in a Changing Regulatory Landscape
Lyophilized Products Are on the Rise: Here’s What You Need to Know
How to Mitigate Risk for Biologics During Fill/Finish Manufacturing
Posted Date: 11/30/2022
This record has been viewed 4625 times.